Challenges in the Development and Reimbursement of Personalized Medicine - Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research

Challenges in the Development and Reimbursement of Personalized Medicine - Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Development and Reimbursement Working Group

The citation for this paper is:
Faulkner E, Annemans L, Garrison L, et al. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value Health 2012; 8: 1162-1171.

Developed by the Personalized Medicine Development and Reimbursement Working Group

Chair:

Eric Faulkner, MPH, Director, Global Market Access, Quintiles Global Consulting, Durham, NC, USA

Leadership Group:

Lieven Annemans, PhD, MSc, Health Economist, Ghent University, Ghent, Belgium
Finley Austin, PhD, BS, US Head External Innovation Environment, Roche, Nutley, NJ USA
Pat Deverka, MD, MS, Research Associate Professor, University of North Carolina, Chapel Hill, NC USA
Lou Garrison, PhD, Professor, University of Washington, Seattle, WA USA
Mark Helfand, MD, MPH, Director, Oregon EPC, Portland, OR USA
Anke Peggy Holtorf, PhD, MBA, Managing Director, BioBridge Strategies, LLC., Basel, Switzerland
John C. Hornberger, MD, MS, CEO & President, Cedar Associates LLC and Adjunct Clinical Professor of Medicine Stanford University School of Medicine, Menlo Park, CA USA
Dyfrig Hughes, PhD, MSc, Reader in Pharmacoeconomics, Bangor University, Bangor, Gwynedd, Wales
Tracy Li, PhD, Director, Immunology, Bristol-Meyers Squibb, Co., Princeton, NJ USA
Daniel Malone, PhD, RPh, BS, MS, Professor, University of Arizona, Tucson, AZ USA
Katherine Payne, PhD, Senior Research Fellow, The University of Manchester, Manchester, UK
Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health, University of Health Sciences, Medical Informatics & Technology, Hall, IT, Austria
Adrian Towse, MA, Director, Office of Health, London, United Kingdom
Dave Veenstra, PhD, PharmD, Associate Professor, University of Washington, Seattle, WA USA
John Watkins, PharmD, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA USA

Activities:

What Can We Learn From Successes and Failures in Personalized Medicine? Implications for Evolving Health Economics and Outcomes Research Practices
May 2011 - ISPOR 16th Annual International Meeting, Baltimore, Maryland, USA

Are Diagnostics and Personalized Medicine in Flux? Implications of Global Policy Changes for Health Economics and Outcomes Research
November 2010 - ISPOR 13th Annual European Congress, Prague, Czech Republic

ISSUES AND CHALLENGES IN THE DEVELOPMENT AND REIMBURSEMENT OF PERSONALIZED MEDICINE: HOW CAN HEALTH ECONOMICS AND OUTCOMES RESEARCH HELP?
May 2010 - ISPOR 15th Annual International Meeting, Forum Presentation, Atlanta, Georgia


Special Interest Groups Index